Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Middle Yanchang Road, Shanghai, 200072, China.
National Metabolic Management Center, Shanghai, 200072, China.
Obes Surg. 2019 Sep;29(9):2862-2868. doi: 10.1007/s11695-019-03914-4.
Lipocalin-2 (LCN2) plays an important role in the regulation of the obesity and obesity-related dysmetabolic state. This study aimed to analyze serum LCN2 level in Chinese women with obesity before and after laparoscopic sleeve gastrectomy (LSG) and determine the association between alteration in fat mass and bone mineral density (BMD) and LCN2 level.
Fifty-two women (38 patients with obesity and 14 with normal body mass index (BMI)) were enrolled in this study. All patients with obesity underwent LSG. BMDs of the arm, leg, thoracic and lumbar spine, and pelvis were measured by dual-energy X-ray absorptiometry. Body fat mass and distribution were measured by dual-energy X-ray absorptiometry, and routine anthropometric/laboratory biochemical parameters at baseline and 3 and 12 months after LSG were recorded. Serum LCN2 levels were measured using an enzyme-linked immunosorbent assay.
Serum LCN2 level was significantly higher in women with obesity than in the controls with normal BMI (102.70 ± 27.19 vs. 80.66 ± 19.55 ng/mL, P = 0.009). LCN2 level was decreased at 3 and 12 months after LSG (86.73 ± 26.79 ng/mL, P = 0.171, and 64.79 ± 28.39 ng/mL, P < 0.001, respectively). LSG led to marked body fat mass and slight BMD decrease. Decreased LCN2 level was significantly correlated with alterations in left and right leg BMDs and trunk fat mass at 12 months after LSG.
Obesity was associated with up-regulated serum LCN2 level. Decreased LCN2 level was positively correlated with changes in BMD and fat mass at 12 months after LSG in Chinese women.
脂联素-2（LCN2）在调节肥胖和肥胖相关代谢异常状态中发挥重要作用。本研究旨在分析中国肥胖女性腹腔镜袖状胃切除术（LSG）前后血清 LCN2 水平，并确定脂肪量和骨密度（BMD）变化与 LCN2 水平之间的关系。
本研究纳入 52 名女性（38 名肥胖患者和 14 名体重指数正常的患者）。所有肥胖患者均接受 LSG。通过双能 X 线吸收法测量手臂、腿部、胸腰椎和骨盆的 BMD。通过双能 X 线吸收法测量体脂肪量和分布，记录 LSG 前和 LSG 后 3 个月和 12 个月的常规人体测量/实验室生化参数。使用酶联免疫吸附试验测量血清 LCN2 水平。
肥胖女性的血清 LCN2 水平明显高于体重指数正常的对照组（102.70±27.19 vs. 80.66±19.55 ng/mL，P=0.009）。LSG 后 3 个月和 12 个月时，LCN2 水平降低（86.73±26.79 ng/mL，P=0.171，64.79±28.39 ng/mL，P<0.001）。LSG 导致显著的体脂肪量减少和轻微的 BMD 下降。LSG 后 12 个月时，LCN2 水平降低与左右腿 BMD 和躯干脂肪量的变化显著相关。
肥胖与血清 LCN2 水平升高有关。LSG 后 12 个月时，LCN2 水平降低与 BMD 和脂肪量的变化呈正相关。
